Faculty: Jonathan Zager, MD, FACS
Release Date: 12/31/2014
The Dermatology Nurse’s Association (DNA) supports the recommendation that the FDA include Alopecia Areata (AA) as a priority for research in the patient-focused drug development initiative being conducted as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). Alopecia Areata affects approximately two percent of the population overall, including more than 5 million people in the United States alone (National Alopecia Areata Foundation). Read the full letter to the FDA here.